HEPES sodium
Based on 11 publication(s) in Google Scholar
HEPES sodium, a nonvolatile zwitterionic chemical buffering agent, is broadly applied in cell culture. HEPES sodium is effective at pH 6.8 to 8.2. HEPES sodium is also a potent inducer of lysosome biogenesis.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 75277-39-3
- Formula: C8H17N2NaO4S
- Molecular Weight:260.29
-
Storage:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) HEPES sodium
More- Cancer Res. 2026 Feb 9. [Abstract]
- Neuron. 2025 Jul 29:S0896-6273(25)00509-4. [Abstract]
- J Adv Res. 2024 Aug 17:S2090-1232(24)00363-1. [Abstract]
- Chin Med. 2025 Jun 16;20(1):89. [Abstract]
- Biochem Pharmacol. 2026 Mar 22:249:117925. [Abstract]
- Bioorg Chem. 2026 Jun 19:180:110125. [Abstract]
- Int Immunopharmacol. 2023 Jul:120:110292. [Abstract]
- Int Immunopharmacol. 2022 Sep:110:108953. [Abstract]
- Structure. 2024 Dec 5;32(12):2287-2300.e4. [Abstract]
- Andrology. 2024 May 22. [Abstract]
- SSRN. 2026 May 6.
Biological Activity
HEPES maintains superhydrophilicity of titanium for at least 3 months and resulted in a continuous retention of bioactivity and osteoconductivity[1].
HEPES drives lysosome biogenesis, affects MiT/TFE cytoplasmic-nuclear distribution, disrupts global cellular transcriptional profiles, resulting the activation of a MiT/TFE-dependent lysosomal-autophagic gene network in cultured RAW264.7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 75277-39-3
-
Appearance Solid
-
Molecular Weight 260.29
-
Formula C8H17N2NaO4S
-
Color White to off-white
-
SMILES
O=S(CCN1CCN(CCO)CC1)(O[Na])=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition. [Abstract]2026 Feb 9. PMID: 41661652 -
Neuron
Social interaction in mice suppresses breast cancer progression via a corticoamygdala neural circuit. [Abstract]2025 Jul 29:S0896-6273(25)00509-4. PMID: 40752486 -
J Adv Res
Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC. [Abstract]2024 Aug 17:S2090-1232(24)00363-1. PMID: 39159723 -
Chin Med
Quercetagetin alleviates liver fibrosis in non-alcoholic fatty liver disease by promoting ferroptosis of hepatic stellate cells through GPX4 ubiquitination. [Abstract]2025 Jun 16;20(1):89. PMID: 40524220 -
Biochem Pharmacol
Recruitment of tumor-associated macrophages via the CCL4-CCR5 axis promotes immune escape through PD-1 signaling in lung adenocarcinoma. [Abstract]2026 Mar 22:249:117925. PMID: 41876018 -
Bioorg Chem
Accelerated development of 4-HPPD inhibitors using a hybrid deep learning approach with Bayesian-guided reinforcement learning. [Abstract]2026 Jun 19:180:110125. PMID: 42348944 -
Int Immunopharmacol
2023 Jul:120:110292. PMID: 37182452 -
Int Immunopharmacol
Neobavaisoflavone inhibits allergic inflammatory responses by suppressing mast cell activation. [Abstract]2022 Sep:110:108953. PMID: 35724607 -
Structure
2024 Dec 5;32(12):2287-2300.e4. PMID: 39426373 -
Andrology
Cellular mechanism underlying leptin-induced anion secretion of rat epididymal epithelial cells. [Abstract]2024 May 22. PMID: 38778669 -
Solvent & Solubility
DMSO : 25 mg/mL (96.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Suzuki T, et al. Nonvolatile buffer coating of titanium to prevent its biological aging and for drug delivery. Biomaterials. 2010;31(18):4818-4828. [Content Brief]
[2]. Sledź P, et al. An experimental charge density of HEPES. Acta Crystallogr B. 2010;66(Pt 4):482-492. [Content Brief]
[3]. https://pubmed.ncbi.nlm.nih.gov/20631430/ [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8419 mL | 19.2093 mL | 38.4187 mL | 96.0467 mL |
| 5 mM | 0.7684 mL | 3.8419 mL | 7.6837 mL | 19.2093 mL | |
| 10 mM | 0.3842 mL | 1.9209 mL | 3.8419 mL | 9.6047 mL | |
| 15 mM | 0.2561 mL | 1.2806 mL | 2.5612 mL | 6.4031 mL | |
| 20 mM | 0.1921 mL | 0.9605 mL | 1.9209 mL | 4.8023 mL | |
| 25 mM | 0.1537 mL | 0.7684 mL | 1.5367 mL | 3.8419 mL | |
| 30 mM | 0.1281 mL | 0.6403 mL | 1.2806 mL | 3.2016 mL | |
| 40 mM | 0.0960 mL | 0.4802 mL | 0.9605 mL | 2.4012 mL | |
| 50 mM | 0.0768 mL | 0.3842 mL | 0.7684 mL | 1.9209 mL | |
| 60 mM | 0.0640 mL | 0.3202 mL | 0.6403 mL | 1.6008 mL | |
| 80 mM | 0.0480 mL | 0.2401 mL | 0.4802 mL | 1.2006 mL |
HEPES sodium Related Classifications
HY-108535 Related Classifications
Powered by Bioz